Disruptive Technology Bringing Diagnostics to the Home | Health Logic (CHIP.H)
Health Logic Interactive Inc (CVE:CHIP.H, OTCMKTS:CHYPF) is developing point-of-care, lab-on-chip, digital diagnostic tools for screening of chronic kidney disease (CKD).
Chronic kidney disease, also called chronic kidney failure, describes the gradual loss of kidney function. Unfortunately, this condition is largely undiagnosed. In the early stages of chronic kidney disease, there may be few signs or symptoms and may not become apparent until your kidney function is significantly impaired. The rapidly progressive disease is notoriously hard to treat or identify and its testing is largely inaccurate, costly, and doesn’t provide specific quantitative measurement for patients.
Health Logic is changing all of that with its disruptive technology. Its digital diagnostic tools are low-cost, accessible, and easily displayed on a smartphone. Lab-on-chip is the size of a credit card and can measure specific biomarkers needed to inform medical decision-making.
Health Logic is bridging the wide screening gap in the diagnostic industry. Historically, it’s been difficult for patients to visit a lab and the pandemic has only escalated the need for point-of-care technology. Health Logic’s technology allows patients to perform tests at home with the ability to collect and manage their own data.
Bringing the lab to each patient’s home provides earlier diagnosis which leads to earlier therapy.
“To the investors that are listening, this hits three hot areas right now. This hits point-of-care, lab-on-chip and it’s a digital health care play of it as well. We are combining three major components into one. This will be a Class 2 medical device that will be diagnostic for chronic kidney disease. – Health Logic Interactive CEO David Barthel”
Watch the full interview to learn about lab-on-chip technology, its benefits to patients, and Health Logic’s timeline until its technology is publicly available.
Related Articles
Disclosure
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.
